The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
The company expects to garner clearance for its platform in the US first for Lynch syndrome as it builds additional evidence for an immunotherapy application.
In PNAS this week: genetic variants linked to a pediatric periodic fever syndrome, TERT promoter mutations influencing BRAF and MEK inhibitor response, and more.
The company and the Harvard TH Chan School of Public Health will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon.
The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
